McKesson Co. (MCK) Expected to Post Earnings of $3.18 Per Share
Equities analysts expect McKesson Co. (NYSE:MCK) to post earnings of $3.18 per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for McKesson’s earnings, with estimates ranging from $3.02 to $3.30. McKesson posted earnings of $3.41 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 6.7%. The firm is scheduled to announce its next earnings report on Thursday, February 7th.
According to Zacks, analysts expect that McKesson will report full-year earnings of $13.41 per share for the current fiscal year, with EPS estimates ranging from $13.27 to $13.53. For the next year, analysts anticipate that the business will report earnings of $14.16 per share, with EPS estimates ranging from $13.90 to $14.34. Zacks’ EPS calculations are a mean average based on a survey of research firms that that provide coverage for McKesson.
McKesson (NYSE:MCK) last announced its quarterly earnings data on Thursday, October 25th. The company reported $3.60 earnings per share for the quarter, beating analysts’ consensus estimates of $3.28 by $0.32. The firm had revenue of $53.08 billion for the quarter, compared to analyst estimates of $53.56 billion. McKesson had a net margin of 0.06% and a return on equity of 26.55%.
Shares of MCK traded down $1.42 during trading hours on Thursday, reaching $127.47. 1,349,478 shares of the company traded hands, compared to its average volume of 1,688,696. The firm has a market capitalization of $25.49 billion, a PE ratio of 10.10, a price-to-earnings-growth ratio of 1.48 and a beta of 1.05. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.56. McKesson has a 12-month low of $117.19 and a 12-month high of $178.86.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 2nd. Investors of record on Monday, December 3rd will be given a dividend of $0.39 per share. The ex-dividend date is Friday, November 30th. This represents a $1.56 dividend on an annualized basis and a yield of 1.22%. McKesson’s dividend payout ratio is presently 12.36%.
In related news, Director N Anthony Coles sold 1,350 shares of the business’s stock in a transaction on Friday, August 31st. The shares were sold at an average price of $128.69, for a total transaction of $173,731.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.87% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Boston Partners raised its position in shares of McKesson by 54.5% in the second quarter. Boston Partners now owns 6,237,042 shares of the company’s stock worth $832,021,000 after acquiring an additional 2,200,669 shares during the period. Vulcan Value Partners LLC raised its position in shares of McKesson by 7.8% in the second quarter. Vulcan Value Partners LLC now owns 3,768,099 shares of the company’s stock worth $502,664,000 after acquiring an additional 273,090 shares during the period. Pzena Investment Management LLC raised its position in shares of McKesson by 11.4% in the third quarter. Pzena Investment Management LLC now owns 3,160,195 shares of the company’s stock worth $419,200,000 after acquiring an additional 323,485 shares during the period. Baupost Group LLC MA raised its position in shares of McKesson by 33.7% in the third quarter. Baupost Group LLC MA now owns 2,175,700 shares of the company’s stock worth $288,607,000 after acquiring an additional 548,000 shares during the period. Finally, Kiltearn Partners LLP raised its position in shares of McKesson by 9.1% in the third quarter. Kiltearn Partners LLP now owns 2,040,651 shares of the company’s stock worth $270,692,000 after acquiring an additional 170,753 shares during the period. Institutional investors own 88.34% of the company’s stock.
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Featured Story: How much money do you need to begin day trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.